Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial


Gerstein H. C., Yusuf S., Holman R. R., Bosch J., Anand S., Avezum A., ...Daha Fazla

LANCET, cilt.368, sa.9541, ss.1096-1105, 2006 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 368 Sayı: 9541
  • Basım Tarihi: 2006
  • Doi Numarası: 10.1016/s0140-6736(06)69420-8
  • Dergi Adı: LANCET
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1096-1105
  • İstanbul Üniversitesi Adresli: Evet

Özet

Background Rosiglitazone is a thiazolidinedione that reduces insulin resistance and might preserve insulin secretion. The aim of this study was to assess prospectively the drugs ability to prevent type 2 diabetes in individuals at high risk of developing the condition.